Tag Archives: Coronavirus

India sees early vaccine launch as AstraZeneca deliveries run late

By Krishna N. Das

NEW DELHI (Reuters) – India raced ahead with work on its coronavirus vaccine while Britain’s AstraZeneca said its deliveries were running “a little bit late” as countries around the world sought to conquer the pandemic and rescue their economies.

A vaccine is seen as the world’s best bet for taming a virus that has infected more than 48 million people, led to more than 1.2 million deaths, roiled economies and disrupted billions of lives since it was first identified in China in December.

Australia is beefing up its prospective arsenal against the pandemic to 135 million doses of various vaccine candidates.

“We aren’t putting all our eggs in one basket,” Prime Minister Scott Morrison said on Thursday.

Some 45 vaccine candidates are in human trials worldwide, with Pfizer Inc saying it could file in late November for U.S. authorization, opening up the possibility of a vaccine being available in the United States by the end of the year.

Moderna and AstraZeneca are close behind the largest U.S. drugmaker and are likely to have early data on their vaccine candidates before the end of the year.

An Indian government-backed vaccine could be launched as early as February – months earlier than expected – as last-stage trials begin this month and studies have so far showed it is safe and effective, a senior government scientist told Reuters.

Bharat Biotech, a private company that is developing COVAXIN with the government-run Indian Council of Medical Research (ICMR), had earlier hoped to launch it only in the second quarter of next year.

“The vaccine has shown good efficacy,” senior ICMR scientist Rajni Kant, who is also a member of its COVID-19 task force, said at the research body’s New Delhi headquarters.

“It is expected that by the beginning of next year, February or March, something would be available.”

Bharat Biotech could not immediately be contacted.

A launch in February would make COVAXIN the first India-made vaccine to be rolled out.

VACCINE KEPT FROZEN

AstraZeneca has signed multiple deals to supply more than three billion doses of its candidate to countries around the world.

But a summer dip in British coronavirus infections had pushed back test results, leading the drugmaker to delay deliveries of shots to the government.

Britain’s vaccines chief said on Wednesday it would receive just 4 million doses of the potential vaccine this year, against initial estimates for 30 million by Sept. 30.

AstraZeneca said on Thursday it was holding back deliveries while it awaits the data from late-stage clinical trials in order to maximize the shelf-life of supplies.

“We are a little bit late in deliveries, which is why the vaccine has been kept in frozen form,” CEO Pascal Soriot said on a conference call.

AstraZeneca and its partner on the project, the University of Oxford, said that data from late-stage trials should land this year.

The United States leads the world in both the number of COVID deaths and infections and the pandemic was a polarizing issue in Tuesday’s presidential election in which votes were still being counted.

Australia’s Morrison said the government would buy 40 million vaccine doses from Novavax and 10 million from Pfizer and BioNTech.

That adds to the 85 million doses Australia has already committed to buy from AstraZeneca and CSL Ltd should trials prove successful.

Among other vaccine candidates around the world, a growing number of Russians are unwilling to be inoculated once a vaccine becomes widely available, the Levada Centre, Russia’s only major independent pollster, said this week.

Russia, raising eyebrows in the West, is rolling out its “Sputnik V” vaccine for domestic use despite the fact that late-stage trials have not yet finished.

(Reporting by Reuters bureaus; Writing by Nick Macfie; Editing by Angus MacSwan)

Analysis: Trump or Biden, new U.S. president faces troubled economy

By Ann Saphir and Jonnelle Marte

(Reuters) – It’s still not clear yet if the next U.S. president will be incumbent Donald Trump or Democratic challenger Joe Biden, but whoever triumphs will face monumental challenges on the economic front.

The recession has been ugly. It has wiped away more than a year of economic output and more than five years of jobs growth.

The workforce is now smaller than it was a year before Trump first took office.

One bright spot – consumer spending – is stronger than it was right after the pandemic exploded in March, but still only back to where it was last June.

Housing prices are on the rise, which is a great thing for U.S. homeowners but at the same time is worsening the affordability crisis for aspiring home buyers.

Manufacturing activity – a key concern in the Midwestern battleground states – has rebounded, but manufacturing employment is in worse shape than employment overall.

And the coronavirus is still surging across most of the United States. Nearly 6,000 people died last week, and there’s growing concern that the U.S. might need to reinstate lockdowns that happened across Europe in order to get it under control.

But despite signs the economy has begun to slow again amid another viral onslaught, “it is almost certain that the economy will get better over the course of 2021,” says Jason Furman, a key economic advisor to Barack Obama, the last U.S. president elected during a time of economic turmoil.

Late 2021 is still a long ways away, not just in political terms but for those living paycheck to paycheck, or out of work.

Federal Reserve policymaker projections put unemployment at 5.5% by the end of next year – worse than the 4.7% when Trump was first elected, but an improvement over the current 7.9%.

Beyond jobs lost and economic output curtailed, either Trump or Biden will face a list of long-term headwinds including deepening inequality, rising federal debt and tattered international trade relations.

In the run-up to the election, Trump consistently polled better than Biden on his ability to create jobs and manage the economy, if not the virus.

But even with the election outcome uncertain, and likely to remain so for some time amid legal challenges, stock market investors like what they see.

That’s partly because Republicans look likely to keep their hold on the Senate, leaving policy priorities relatively unchanged if it’s Trump emerging the winner, or as preventive force to a president Biden from trying to push through any big policy changes should he come out on top in the ballot box.

It’s also because Senate Majority Leader Republican Mitch McConnell signaled Wednesday he was open to a new coronavirus aid bill in the “lame duck” session before the elected members of Senate and U.S. House of Representatives are sworn in.

For the still-weak economy, a lot will depend on the timing, size and shape of a pandemic relief package, which eluded lawmakers and the White House before the election.

A more modest fiscal package could mean “the growth outlook and corporate profits may not be as vigorous as hoped,” said James Knightley, chief international economist for ING.

A Biden presidency with a majority Republican Senate could offer the worst case for the economy in 2021 because Republicans are likely to oppose a substantial stimulus package, said Matthew Luzzetti, chief U.S. economist at Deutsche Bank.

That would be bad news for the millions of low- and middle-income Americans out of work and struggling to find jobs in sectors such as travel and entertainment that are likely to remain moribund until the pandemic is under better control.

A scenario where Trump is re-elected and the Senate stays in Republican control could potentially result in more stimulus because Trump has advocated for more stimulus and could have more sway if he is re-elected, Luzzetti said.

Whatever the election outcome, any aid package should provide additional assistance for the unemployed, help for small businesses and assistance for state and local governments, to keep economic momentum going, Luzzetti said.

(Reporting by Ann Saphir and Jonnelle Marte; Editing by Heather Timmons, Paul Simao and Edward Tobin)

In COVID-19 clampdown, China bars travelers from Britain, France, India

BEIJING (Reuters) – China has barred non-Chinese travelers from Britain, France, Belgium, the Philippines and India, imposing some of the most stringent entry curbs of any country as coronavirus cases surge around the world.

The restrictions, which cover those with valid visas and residence permits and take effect in conjunction with a more restrictive testing regime for arrivals from several other countries, drew a frosty response from Britain.

“We are concerned by the abruptness of the announcement and the blanket ban on entry, and await further clarification on when it will be lifted,” said the British Chamber of Commerce in China as the blanket bans were announced by the five countries’ Chinese embassies.

England started a month-long lockdown on Thursday. Britain’s virus death toll is the highest in Europe, and it is grappling with more than 20,000 new cases a day.

Belgium has Europe’s highest per capita number of new confirmed cases, while France and India are among the top five countries in the world with the most infections.

The suspensions were a partial reversal of an easing on Sept. 28, when China allowed all foreigners with valid residence permits to enter. In March, China had banned entry of foreigners in response to the epidemic.

‘SOLD OUT IN SECONDS’

Meanwhile, many people planning November visits to China scrambled to book earlier flights to circumvent potentially disruptive restrictions due to come into force for other countries from Friday.

Linyi Li, a Chinese national, had planned to fly from Seattle to China in mid-November but switched her flight to Nov. 6 even though fares had tripled.

“The tickets were sold out in seconds, as people were all scrambling to beat the deadline,” said Li, 30. “I’ve been rushing to sell many of my family belongings in the past days in case I can’t get back to the States.”

From Friday, all passengers from the United States, France, Germany and Thailand bound for mainland China must take a nucleic acid test and a blood test for antibodies against the coronavirus no more than 48 hours before boarding.

Flights scheduled for Friday are not covered by the new rule, since passengers would have done their tests before that day under previous requirements.

China also plans to impose dual-test requirements on travelers from Australia, Singapore and Japan from Nov. 8.

The European Union Chamber of Commerce in China said the antibody test was not widely available in many countries.

“(So) unfortunately, while technically leaving the door open, these changes imply a de facto ban on anyone trying to get back to their lives, work and families in China,” said the European Union Chamber of Commerce in China.

On Tuesday, China Southern Airlines, the country’s biggest carrier by passenger load, said it would suspend transit services for passengers embarking from 21 countries, mostly African and Asian countries and including India and the Philippines.

The number of weekly international passenger flights serving mainland China from late October through March is set to slump 96.8% from a year earlier to 592, the latest schedules show.

(Reporting by Ryan Woo, Lusha Zhang, Dominique Patton, Stella Qiu, Gabriel Crossley, Martin Pollard and Shivani Singh; Editing by Jacqueline Wong and John Stonestreet)

Britain prepares for COVID-19 vaccine as Oxford forecasts result this year

By Alistair Smout and Guy Faulconbridge

LONDON (Reuters) – Late-stage trial results of a potential COVID-19 vaccine being developed by the University of Oxford and AstraZeneca could be presented this year as the British government prepares for a possible vaccination rollout in late December or early 2021.

A vaccine is seen as a game-changer in the battle against the coronavirus, which has killed more than 1.2 million people worldwide, shuttered swathes of the global economy and turned normal life upside down for billions of people.

There are more than 200 candidates under development and the vaccine being developed by Oxford and licensed to British drugmaker AstraZeneca is seen as a front-runner.

“I’m optimistic that we could reach that point before the end of this year,” Oxford Vaccine Trial Chief Investigator Andrew Pollard said of the chances of presenting trial results.

Pollard told British lawmakers that establishing whether or not the vaccine worked would likely come this year, after which the data would have to be carefully reviewed by regulators and then a political decision made on who should receive it.

“Our bit – we are getting closer to but we are not there yet,” Pollard, director of the Oxford Vaccine Group, said.

Asked if he expected the vaccine would start to be deployed before Christmas, he said: “There is a small chance of that being possible but I just don’t know.”

The National Health Service (NHS) in England is preparing to start distributing possible COVID-19 vaccines before Christmas in case one is ready by the end of the year.

The Oxford/AstraZeneca vaccine is expected to be one of the first from big pharma to be submitted for regulatory approval, along with Pfizer and BioNTech’s candidate.

“If I put on my rose-tinted specs, I would hope that we will see positive interim data from both Oxford and from Pfizer/BioNTech in early December and if we get that then I think we have got the possibility of deploying by the year end,” Kate Bingham, the chair of the UK Vaccine Taskforce, told lawmakers.

Prime Minister Boris Johnson said there was the prospect of a vaccine in the first quarter of 2021. AstraZeneca is presenting its third quarter financial results on Thursday.

‘GAME CHANGER’

Work on the Oxford viral vector vaccine, called AZD1222 or ChAdOx1 nCoV-19, began in January. It is made from a weakened version of a common cold virus that causes infections in chimpanzees.

The chimpanzee cold virus has been genetically changed to include the genetic sequence of the so-called spike protein which the coronavirus uses to gain entry to human cells. The hope is that the human body will then attack the novel coronavirus if it sees it again.

If Oxford’s vaccine works, it could eventually allow the world to return to some measure of normality.

Asked what success looked like, Pollard said: “Good is having vaccines that have significant efficacy – so whether, I mean, that is 50, 60, 70, 80 percent, whatever the figure is – is an enormous achievement.

“It’s a complete game changer and a success if we meet those efficacy end points,” he said, adding it would relieve pressure on the health system.

But Pollard and Bingham agreed that the world would not return to normal immediately. Asked about the chances of a vaccine that would wipe out the coronavirus next year, Bingham said the prospects were “very slim.”

“(But the chances) to get a vaccine that has an effect of both reducing illness, and reducing mortality (are) very high,” Bingham said, adding she was more than 50% confident there would be such a vaccine by early summer.

(Reporting by Alistair Smout and Guy Faulconbridge; Editing by Nick Macfie and Alexander Smith)

U.S. CDC reports 230,893 deaths from coronavirus

(Reuters) – The U.S. Centers for Disease Control and Prevention (CDC) on Tuesday reported 9,268,818 cases of the novel coronavirus, an increase of 86,190 cases from its previous count, and said that the number of deaths had risen by 510 to 230,893.

The CDC reported its tally of cases of the respiratory illness known as COVID-19 as of 4 p.m. ET on Nov. 2, compared with its previous report released a day earlier.

The CDC figures do not necessarily reflect cases reported by individual states.

(Reporting by Mrinalika Roy in Bengaluru)

As Americans head to the polls, COVID-19’s long shadow looms

By Nick Brown and Ernest Scheyder

(Reuters) – For many Americans, this is the coronavirus election.

The pandemic has killed about 230,000 people in the country and destroyed millions of jobs, defining the last year of Donald Trump’s presidency and becoming a rallying cry for his Democratic opponent, Joe Biden.

Here are stories from a cross-section of Americans – voters and officials – for whom COVID-19 is the driving force in Tuesday’s election. Their stories underscore why the disease casts a long shadow over the 2020 U.S. presidential election.

SONIKA RANDEV, 36, NEW YORK, NEW YORK

Dr. Sonika Randev has had a dark year. In March, when she was a medical resident at New York’s Metropolitan Hospital, Randev contracted COVID-19, spending three weeks battling fever, brain fog, body aches, a loss of taste and smell and what she termed a “bone-chilling cold.”

Afterward, figuring she was immune to the coronavirus, Randev volunteered to care for the hospital’s sickest COVID patients, watching many die.

“My unit became an end-of-life unit,” she said. “We were basically waiting for patients to pass away or go to hospice.”

Melancholy quickly set in.

New York’s nightly ritual – in which people clapped and cheered for healthcare workers from their windows – stopped buoying Randev’s spirits. She found herself shutting her windows to the sound, which only reminded her of “the sea of misery” the city had become. When friends and colleagues took to drowning their sorrows, Randev found drinking only made her feel worse, so she stopped.

She felt powerless.

Now, as she gets back on her feet, she said she is trying to take some of that power back – by voting for Democratic candidate Joe Biden.

“Being able to go to the polls and finally exert some control just by casting a vote, I think that’s something powerful,” Randev said.

Recalling how doctors were forced to reuse the same masks and gowns for days, Randev said Trump should have done more to boost supply of protective gear. She also feels Trump unfairly left state governments to fight the pandemic on their own, then “turned around and criticized” those who imposed strict lockdowns.

In a statement to Reuters in October, a Trump campaign spokeswoman said the president has faced the pandemic “head on,” citing his restrictions on travel from China, adding that “he will not stop until we’ve beaten the coronavirus.”

But Randev does not believe Trump would do any better in a second term. “He is who he is,” she said. “He’s never going to change.”

CHRIS HOLLINS, 34, HOUSTON, TEXAS

It has been less than six months since Chris Hollins was thrust into the job of running elections in Harris County, Texas – the largest county in a historically conservative state that Biden has a chance of flipping.

Already, the new county clerk has battled Texas’ Republican governor and attorney general on voting rights access, underscoring the bitter battle for votes in the second-largest U.S. state.

Hollins launched drive-through voting and kept some early-voting locations open 24/7, largely for the convenience of the county’s large numbers of medical and oil industry workers, who often work odd hours.

A Republican state representative sued Hollins for the county’s use of drive-through voting in both the Texas Supreme Court, which rejected the suit on Sunday, and in federal court, where a judge on Monday ruled against it as well.

Hollins opposed the governor’s order limiting counties to one drop-off location for absentee ballots.

As a public appointee, Hollins cannot publicly endorse a candidate, though he is a Democrat.

Prodded partly by the COVID-19 pandemic, county commissioners boosted the election budget seven fold from 2016 levels to $27.7 million. Hollins used that money to triple the county’s early-voting locations to 120.

Plastic coverings that Hollins’ office bought for voters’ fingers – the county uses touchscreen voting terminals – have gone viral on social media, with some playfully describing them as “finger condoms.”

Hollins said his job is “to make sure every voter in Harris County has an opportunity to cast their ballots and can do so safely.”

He and the county have been largely been successful: By Oct. 29, more county voters had cast early ballots than in the entire 2016 election.

GLORIA “LEE” SNOVER, 52, BETHLEHEM TOWNSHIP, PENNSYLVANIA

Her father died of it. Her mother spent eight days in the ICU; her husband, 17 days. Five others in her family contracted it, including herself. For Lee Snover, COVID-19 was more than a news story. It was a family crisis.

Still, Snover goes to the polls more determined than ever to reelect Trump. The chair of the Republican Committee of Northampton County, Pennsylvania – a crucial swing district Trump won in 2016 – said that despite widespread criticism of the president’s handling of the disease, it never occurred to her to blame him for the pandemic that ravaged her family’s health and hamstrung its construction business.

Snover hit emotional rock-bottom the day of her father’s funeral in April, when, battling her own mild COVID diagnosis, she was forced to stay home. The same day, her husband entered the hospital with worsening symptoms. Her mother would soon join. The virus would ensnare eight family members total.

COVID has infected 5,700 Northampton residents and killed 315, according to Pennsylvania Department of Health data. That is 103 deaths per 100,000 residents, well above the U.S. average.

Snover opposes economic shutdowns, equating them to letting the virus win, even though doctors have said social distancing is the best way to beat COVID. “We see life as you gotta survive, you gotta win. We’re not victims. When something hits us, we beat it back and win,” she said.

With Trump behind in opinion polls, Snover says her last vote as a party official carries special weight.

“All this about women’s rights, and ‘Women are so mighty,’ but I look at them on Facebook and all they talk about is fear,” she said. “Putting my finger on that machine button and casting that ballot — that’s a victory against COVID.”

GARY SIMS, 52, RALEIGH, North Carolina

COVID-19 has caused Gary Sims to lose sleep, weight and time with his daughters – and he hasn’t even had the disease.

As director of elections for Wake County, North Carolina, Sims must stage a vote in the most populous county of a crucial battleground state, in the midst of a public health nightmare. The stress is eating him alive, he said.

From online poll worker training to mailing out hundreds of thousands of absentee ballots, “everything has been unprecedented,” Sims said.

He has had to reconfigure his agency’s 76,000-square-foot headquarters so that it can process five times its usual haul of mail ballots while keeping workers much farther apart than normal.

He has seen his two grown daughters just once this year, even though they live close by – for their own protection, he said, since he can’t work from home and is more exposed to the virus.

No stranger to pressure, the U.S. military veteran saw combat in two foreign conflicts. He worries political tensions could lead to confrontation, or that poll workers – many of whom are first-timers this year – could grow overwhelmed by the added burdens of enforcing social distancing and contending with a high turnout of partisan poll observers.

Sims’ blood pressure has spiked. Struggling to stomach solid foods, he’s subsisted mostly on protein shakes. He has lost 40 pounds (18 kg) in two months. “Did I need to lose the weight?” he said. “Yeah. Did I plan to lose it like that? No.”

As an official in charge of fair elections, Sims cannot reveal his own voting plans, but said he is an independent who votes with his daughters in mind.

“They’re getting their future started,” he said. “So my vote is for what’s best for them.”

ISRAEL SUAREZ, 76, FORT MYERS, FLORIDA

Israel Suarez nearly died after he contracted COVID-19 in August, but he did not let that stop him from voting.

Suarez spent 10 days in a Florida hospital and said he was convinced he was going to die. After the ordeal, the lifelong Republican and native of Puerto Rico voted early in October, an act he called a civic duty.

“The coronavirus shouldn’t stop anyone from exercising their moral and social responsibility to vote,” said Suarez, who founded the Nations Association Charities in Fort Myers, Florida, a nonprofit that runs youth groups and other community outreach programs.

Until now, Suarez has affiliated with Republican causes and politics. But this year, he’s supporting Biden.

“I’m so fed up with this man, Mr. Trump, because I almost died,” Suarez said. “I almost lost my life because of him.”

Suarez said Trump has divided and confused the country by failing to lead it successfully through the pandemic.

Suarez added that he persuaded his wife and daughter to vote for Biden, too. Biden “is a moral man,” Suarez said, “no matter what people think of him.”

(Reporting by Nick Brown and Ernest Scheyder; Editing by Ross Colvin and Cynthia Osterman)

IMF tells G20 countries to “keep spending” on COVID-19 crisis

By Andrea Shalal

WASHINGTON (Reuters) – The International Monetary Fund on Monday warned Group of 20 major economies that the coronavirus crisis is not over and called on the United States, Britain and other countries to increase the amount of fiscal spending currently planned.

Premature withdrawal of fiscal support at a time of continued high rates of unemployment would “impose further harm on livelihoods and heighten the likelihood of widespread bankruptcies, which in turn could jeopardize the recovery,” senior IMF officials warned in a blog published Monday.

The blog, entitled, “The Crisis is Not Over, Keep Spending (Wisely),” said swift and unprecedented action by G20 and emerging market economies had averted an even deeper crisis, with G20 countries alone providing $11 trillion in support.

The IMF last month forecast a 2020 global contraction of 4.4% and a return to growth of 5.2% in 2021, but warned that the situation remained dire and governments should not withdraw stimulus prematurely.

On Monday, it said COVID infections were continuing to spread, but much of the fiscal support provided was now winding down, with cash transfers to households, deferred tax payments and temporary loans to businesses either having expired or being set to do so by year-end.

In economies where deficits dropped by 10% of gross domestic product this year, fiscal balances are expected to narrow by more than 5% of GDP in 2021, largely due to a sharp withdrawal of relief measures, they said.

“Larger support than currently projected is desirable next year in some economies,” the IMF said in a longer report to G20 countries also published Monday. It singled out Brazil, Mexico, Britain and the United States, citing large drops in employment in these economies and projected fiscal contractions.

Democratic lawmakers and Republican President Donald Trump have been unable to reach agreement on a new stimulus package for the United States, the world’s largest economy. New spending may not be agreed until early 2021, depending on the outcome of the presidential election on Tuesday.

The IMF said countries should maintain support for poor and vulnerable groups hit disproportionately hard by the crisis, as well as targeted support for viable firms to maintain employment relationships. It listed India, Mexico, Russia, Saudi Arabia, Turkey and the United States as examples.

However it warned against providing support for firms that hindered a transfer of resources from sectors that may permanently shrink to those sectors that will be expanding.

(Reporting by Andrea Shalal; Editing by Chizu Nomiyama and Nick Macfie)

Europe’s COVID curbs prompt pushback amid bleak countdown to Christmas

By Guy Faulconbridge and Richard Lough

LONDON/PARIS (Reuters) – A wave of COVID lockdowns and curbs has stirred resistance across Europe, with the right-wing British politician who helped force a referendum on Brexit harnessing popular anger at a new lockdown by recasting his Brexit Party under a new banner.

The United Kingdom, which has the highest official death toll in Europe from COVID-19, is grappling with more than 20,000 new coronavirus cases a day and scientists have warned the “worst-case” scenario of 80,000 dead could be exceeded.

Cast by his supporters as the godfather of the movement to quit the European Union, Brexit Party founder Nigel Farage said Johnson had terrified Britons into submission with a second lockdown.

“The single most pressing issue is the government’s woeful response to coronavirus,” Farage and Brexit Party chairman Richard Tice said in a joint article in the Daily Telegraph, announcing his Reform UK party.

“Ministers have lost touch with a nation divided between the terrified and the furious. The debate over how to respond to COVID is becoming even more toxic than that over Brexit.”

Instead of a lockdown, Farage proposed targeting those most at risk and said people should not be criminalized for trying to live normal lives such as meeting family for Christmas.

France, Germany, Italy, Britain, the Netherlands and other countries have announced second lockdowns or strict new curbs as infections surge.

Small shopkeepers in France have complained about being forced to close while supermarkets are allowed to sell “non-essential goods” such as shoes, clothes, beauty products and flowers because they also sell food.

CHRISTMAS CANCELLED?

Finance Minister Bruno Le Maire said on Monday French supermarkets would face the same limits on selling non-essential goods but shop owners were not allowed to challenge the lockdown, in place until at least Dec. 1.

“I am not optimistic that in just four weeks we will lower the number of new cases to the level announced by the president (5,000 new cases per day),” said epidemiologist Dominique Castigliola, director of research at the National Institute of Health and Medical Research.

“We will need more time. I don’t think we’ll be able to hold big family meals at Christmas. That seems very unlikely to me.”

German Chancellor Angela Merkel last week denounced populists who say the coronavirus is harmless as dangerous and irresponsible.

“Throughout the winter months, we will have to limit private contacts,” she told a news conference. “The light at the end of the tunnel is still quite a long way off.”

Police in the Spanish capital, Madrid, on Sunday raided 81 illegal parties, 18 drinking sessions known in Spain as “botellones,” and 10 bars which broke COVID-19 curbs.

Protests flared against new restrictions across Italy last week, with violence reported in Milan and Turin. Italy will tighten restrictions but is holding back from a lockdown, Prime Minister Giuseppe Conte said on Monday.

Italy’s daily tally of infections has increased 10-fold over the last month.

“It is a monumental debacle. The fact that Italy is in the same situation as other countries in Europe is no comfort to me,” virologist Andrea Crisanti told Reuters. “We had five months to strengthen our surveillance, tracking and prevention systems and instead we are heading towards a new lockdown.”

More than 46.37 million people have been infected globally and 1,198,168​ have died from the respiratory disease, according to a Reuters tally. The United States, which holds a presidential election on Tuesday, leads the world with more than 9 million cases and 230,700 deaths.

Iran, the Middle East country worst hit by COVID-19, reported a record 440 deaths in the past 24 hours.

World shares recovered from one-month lows as strengthening factory data in China and Europe offset news of lockdowns, while investors prepared for more volatility arising from the U.S. presidential election.

U.S. President Donald Trump has continually downplayed the virus, mocking Democratic challenger Joe Biden for wearing a mask and social distancing at campaign rallies, a tactic which enlivens his base supporters but infuriates his opponents.

Trump has also ridiculed his top coronavirus task force adviser, Anthony Fauci, who has contradicted Trump’s assertions that the U.S. fight against the virus is “rounding the turn”.

The United States reported 67,862 new cases on Sunday, the highest number it has reported on the last day of any week. The seven-day average hit 81,540, a new record, and has risen for 30 days in a row.

(Reporting by Reuters bureaux worldwide; Writing by Nick Macfie; Editing by Giles Elgood/Mark Heinrich)

With one day left, Trump and Biden search for last-minute support in key states

By Steve Holland and Trevor Hunnicutt

OPA-LOCKA, Fla./WILMINGTON, Del. (Reuters) – U.S. President Donald Trump hunts for support in four battleground states on Monday while Democratic rival Joe Biden focuses on Pennsylvania and Ohio during the final day of campaigning in their race for the White House.

The Republican Trump trails Biden in national opinion polls ahead of Tuesday’s Election Day. But the race in swing states is seen as close enough that Trump could still piece together the 270 votes needed to prevail in the state-by-state Electoral College that determines the winner.

Trump, aiming to avoid becoming the first incumbent president to lose re-election since fellow Republican George H.W. Bush in 1992, will hold five rallies on Monday in North Carolina, Pennsylvania, Wisconsin and Michigan.

He won those states in 2016 against Democrat Hillary Clinton, but polls show Biden is threatening to recapture all four for Democrats.

In a year that has seen much of American life upended by the coronavirus pandemic, early voting has surged to levels never before seen in U.S. elections. A record-setting 94 million early votes have been cast either in-person or by mail, according to the U.S. Elections Project, representing about 40% of all Americans who are legally eligible to vote.

Trump will wrap up his campaign in Grand Rapids, Michigan, the same place he concluded his 2016 presidential run with a post-midnight rally on Election Day.

Biden, running mate Kamala Harris and their spouses will spend most of Monday in Pennsylvania, splitting up to hit all four corners of a state that has become vital to the former vice president’s hopes.

Biden will rally union members and African-American voters in the Pittsburgh area before being joined for an evening drive-in rally in Pittsburgh by singer Lady Gaga.

He also will make a detour to bordering Ohio, spending time on his final campaign day in a state that was once considered a lock for Trump, who won it in 2016, but where polls now show a close contest.

Former President Barack Obama, whom Biden served as vice president for eight years, will hold a get-out-the-vote rally in Atlanta on Monday before closing out the campaign in the evening with a rally in Miami.

Biden has wrapped up the campaign on the offensive, traveling almost exclusively to states that Trump won in 2016 and criticizing the president’s response to the coronavirus pandemic, which has dominated the race.

Biden accuses Trump of giving up on fighting the pandemic, which has killed more than 230,000 Americans and cost millions of jobs. Polls show Americans trust Biden more than Trump to fight the virus.

During a frantic five-state swing on Sunday, Trump – who was impeached by the Democratic-led House of Representatives last December and acquitted by the Republican-controlled Senate in February – claimed he had momentum.

He promised an economic revival and imminent delivery of a vaccine to fight the pandemic.

Dr. Anthony Fauci, the top U.S. infectious diseases expert, has said the first doses of an effective coronavirus vaccine will likely become available to some high-risk Americans in late December or early January.

Trump, who has often disagreed with Fauci publicly, suggested early on Monday he might fire him as director of the National Institute of Allergy and Infectious Diseases after the election.

A ‘TERRIBLE THING’

Trump again questioned the integrity of the U.S. election, saying a vote count that stretched past Election Day would be a “terrible thing” and suggesting his lawyers might get involved.

Americans have already cast nearly 60 million mail-in ballots that could take days or weeks to be counted in some states – meaning a winner might not be declared in the hours after polls close on Tuesday night.

“I don’t think it’s fair that we have to wait for a long period of time after the election,” Trump told reporters. Some states, including battlegrounds Pennsylvania and Wisconsin, do not start processing mail-in votes until Election Day, slowing the process.

Trump has repeatedly said without evidence that mail-in votes are prone to fraud, although election experts say that is rare in U.S. elections. Mail voting is a long-standing feature of American elections, and about one in four ballots was cast that way in 2016.

Democrats have pushed mail-in voting as a safe way to cast a ballot in the coronavirus pandemic, while Trump and Republicans are counting on a big Election Day in-person turnout.

Both campaigns have created armies of lawyers in preparation for post-election litigation battles.

“We’re going in the night of – as soon as the election is over – we’re going in with our lawyers,” Trump told reporters without offering further explanation.

The attorneys general of Michigan and Pennsylvania, both Democrats, challenged Trump’s rhetoric on Twitter.

“The election ends when all the votes are counted. Not when the polls close,” Michigan Attorney General Dana Nessel wrote.

In a sign of how volatile the election could be, buildings for blocks around the White House were boarded up over the weekend. Federal authorities planned to extend the perimeter fencing around the White House to by several blocks, encompassing the same area fenced out during this summer’s protests against racism and police brutality, according to U.S. media.

To help ensure mail-in ballots are delivered in a timely fashion, a U.S. judge on Sunday ordered the U.S. Postal Service to remind senior managers they must follow its “extraordinary measures” policy and use its Express Mail Network to expedite ballots.

A federal judge in Texas on Monday will consider a Republican request to throw out about 127,000 votes already cast at drive-through voting sites in the Democratic-leaning Houston area.

The FBI, meanwhile, is investigating an incident in Texas when a pro-Trump convoy of vehicles surrounded a tour bus carrying Biden campaign staff. The caravan, which Trump praised, prompted the Biden campaign to cancel at least two of its Texas events, as Democrats accused the president of encouraging supporters to engage in acts of intimidation.

(Reporting by Steve Holland in Opa-Locka, Florida, and Trevor Hunnicutt in Wilmington, Delaware; Writing by John Whitesides; Editing by Scott Malone and Alistair Bell)

EU urged to review remdesivir supply deal after COVID trial results

By Francesco Guarascio

BRUSSELS (Reuters) – The European Union should renegotiate a 1 billion euro ($1.17 billion) contract it sealed last week with Gilead for a six-month supply of the COVID-19 drug remdesivir after it showed poor results in a large trial, experts said on Friday.

In a blow to one of the few drugs being used to treat people with COVID-19, the Solidarity Trial conducted by the World Health Organization showed on Friday that remdesivir appeared to have little or no effect on mortality or length of hospital stays among patients with the respiratory disease.

The trial results were disclosed a week after the EU’s executive Commission announced its largest contract to date with Gilead for the supply of 500,000 courses of the antiviral drug at a price of 2,070 euro per treatment, which Gilead said was the standard for wealthy nations.

The Commission “needs to present the reasons behind the rush to conclude the latest contract with Gilead and move to review it in light of the Solidarity Trial findings,” said Yannis Natsis, who represents patients’ organizations on the board of the European Medicines Agency (EMA), the EU drug regulator.

The EU announced on Oct. 8 that it had signed the supply contract with the U.S. company on behalf of its 27 member states and 10 partner countries, including Britain.

Gilead had known about the results of Solidarity since Oct. 6, the WHO said, citing disclosure rules under the Solidarity Trial.

Gilead told Reuters it had received in late September an “heavily redacted manuscript” from the WHO which contained different information from the final document published on Friday.

“TIME IS OF THE ESSENCE”

The Commission’s decision was made after EU countries warned of shortages of remdesivir in their hospitals amid a new surge of COVID-19 infections across Europe.

The contract does not oblige countries to buy remdesivir, although it ties them to the agreed price.

Gilead did not comment on whether remdesivir’s price for wealthy countries could change after the WHO trial, and the company questioned its results.

“As time is of the essence – we are in a situation of a public health emergency – we have to not only invest up-front in vaccine development but also in access to therapeutics,” a spokesman for the European Commission said.

He added the EMA would look into the Solidarity results and data available from other studies on COVID treatments “to see if any changes are needed to the way these medicines are used”.

But the spokesman did not comment on whether the EU was aware of the Solidarity results before it signed the contract with Gilead. He also did not reply to questions on whether the price agreed with Gilead could be renegotiated.

“The EU should revisit the prices to be paid for Remdesivir. Why pay 1 billion euros for a drug with no effects on survival?” said Andrew Hill, a senior visiting research fellow in the Department of Pharmacology at the University of Liverpool.

He said generic versions of the drug manufactured in India were sold at 200 euros per course.

(Reporting by Francesco Guarascio @fraguarascio; additional reporting by John Miller; Editing by Gareth Jones)